Finally, our results confirm how TRK inhibitors represent a significant therapeutic strategy for metastatic cancer patients harboring an NTRK gene fusion, and, thus, all the cancer patients harboring this molecular alteration should be evaluated for specific inhibitors [74]. This evidence concerns the gene NTRK1 and metastatic malignant neoplasm.